Intercostal nerve blocks are an effective method of providing analgesia following both thoracic and abdominal incisions. This technique has been used successfully at this centre for several years to provide analgesia and reduce opioid requirements in patients after liver transplantation. There are, however, only limited data on the use of local anaesthetic agents in patients with liver disease. Patients with severe liver disease develop portal hypertension and extensive collateral vessel formation. The effects of these enlarged vessels on the rate of drug absorption is not known. In addition, the ability of the recently transplanted liver to metabolize drugs has not been established.
The long duration of action of bupivacaine makes it the drug of choice for intercostal nerve block. We therefore measured total plasma concentrations of bupivacaine after intercostal blocks in patients who had undergone liver transplantation. Two groups were studied using bupivacaine with and without adrenaline, and after single and repeated injections.
PATIENTS AND METHODS
Eleven patients who required analgesia on the first or second day after liver transplantation were allocated consecutively to two groups:
Group 1 comprised six patients given a single set of bilateral intercostal nerve blocks using plain bupivacaine 2 mg kg" 1 . Group 2 consisted of six studies in five patients having two sets of bilateral intercostal nerve blocks separated by 6 h using bupivacaine with adrenaline 1:200000 (2 mg kg" 1 for each set of injections). One patient was studied on two occasions, 4 months apart, after her first and second liver transplant.
Approval was obtained for the study from the hospital Ethics Committee and written informed consent was obtained before operation from each patient. The intercostal nerve blocks were performed when the patient was ready for tracheal extubation, usually on the first day after operation. A baseline blood sample was withdrawn from a radial arterial cannula, inserted previously for other purposes. Bilateral intercostal nerve blocks (T5-T10) were performed using a standard technique [1] by the same operator (A.B.). In smaller, wasted patients the dose of bupivacaine was made up to a minimum volume of 30 ml allowing an adequate volume of solution. Arterial blood (5 ml) was sampled at 5, 10, 15, 30, 60, 120, 240 and 480 min after injection of bupivacaine. In group 2 an extra sample was taken at 2.5 min and the final sample taken at 360 min, immediately before the intercostal blocks were repeated. Blood was collected in tubes containing lithium heparin as an anticoagulant and centxifuged at 3000 #. Plasma was stored at -20 °C until required for analysis. Liver function tests (albumin, total protein and alpha-1-acid-glycoprotein (AGP)) were measured also in a baseline serum sample. Any adverse reactions such as changes in arterial pressure or neurological deterioration were recorded during this period. Detailed neurological assessment was not possible because of residual effects of opioids and benzodiazepines and the process of tracheal extubation. Care of the patient was, in all other respects including other drug therapy, as described previously [2] .
Bupivacaine concentrations in groups 1 and 2 were compared by Student's t test for paired data. The relationship between bupivacaine concentrations and AGP concentrations was determined using linear regression analysis. Values are given as mean (SEM) except where indicated.
Analysis of samples
The assay was performed using HPLC as described by Nation, Peng and Chion [3] . After the addition of an internal standard (etidocaine), the sample was alkalinized with sodium hydroxide and extracted with dichloromethane. An aliquot of extract was evaporated to dryness at 50 °C and redissolved in a mobile phase of 1 % triethylamine in water, adjusted to pH 3.0 with phosphoric acid and organic modifier (30% acetonitrile) before injection. The solution was injected onto a 150x4.6-mm column containing 5-um ultrasphere "ods" and the flow rate was adjusted to 1.5 ml min" 1 at ambient conditions. An ultraviolet detector as 205 nm was used. The assay was calibrated with spiked standards. All patients were receiving different medications, including morphine, midazolam, dopamine, prednisolone, azathioprine, cefotaxime, tobramycin, nystatdn, ranitidine, folic acid and vitamin K. Control samples of serum from other liver transplant recipients who had not received bupivacaine revealed no interference with the assay. In addition to this study a further 2000 samples have been analysed and no interference from other substances detected [J. Goudie, personal communication]. The sensitivity of the assay was 50 ng ml" 1 with a within-batch variation of 3.9 % and a between-batch variation of 4.0 %.
The AGP assay was performed by automated turbidimetric immunoassay using an IL Monarch analyser utilizing "Dako" antiserum to AGP.
Analysis of areas under the concentration-time curves were performed using an "Apple Fitter" programme. The values for Tf and clearance in this study were not calculated, as sampling was not carried out for the recommended three elimination half-lives because of the need to repeat the injections for analgesia.
RESULTS
The details of the 11 patients studied are shown in table I. The injections were performed at a mean time of 15.7 (SD 8.5) h after the transplanted liver had been reperfused. The concentrations of plasma proteins and liver function tests at the time of each study are shown in table II. The mean time to complete the bilateral intercostal nerve blocks was 4.5 (SEM 1.8) min.
In group 1 (plain bupivacaine) the mean maximum concentration (Cmax) was 1.75 (SEM 0.07) ug ml" 1 ( fig. 1) . The time at which Cmax was achieved (7max) was 5, 10 and 15 min in three, two and one patients, respectively. The mean value of Cmax, in group 2 (bupivacaine + adrenaline), was 1.69 (0.35) ug ml" 1 after the first injection ( fig. 2) . Tmax. occurred at 5, 10, 15 and 30 min in one, two, two and one patients, respectively. After the second set of injections in group 2, Cmax was 1.99 (0.34) ug ml" 1 . 7*max occurred at 5, 10, 15 and 30 min in two, one, one and two patients, respectively.
Cmax in group 1 was not significantly different from that after the first set of injections in group 2 (P > 0.05), indicating that the use of adrenaline containing solutions did not reliably slow absorption. The plasma concentrations of bupivacaine had not returned to zero after 6 h in group 2, the time when the second set of injections were performed. In addition, the area under the mean concentration-time curve increased by 44% in group 2 after the second set of injections. These two factors indicate cumulation of bupivacaine. Eight patients had serum concentrations of AGP greater than the reference range (table II) , but these increased concentrations did not correlate with the measured concentrations of total bupivacaine (P > 0.05). The patient who was studied twice had similar plasma concentrations of bupivacaine on each occasion.
DISCUSSION
Intercostal nerve blocks using bupivacaine are an effective method of providing analgesia following liver transplantation and are used routinely at this centre [2] . The technique is chosen in order to limit the dose of opioid. There has been one other short report of intercostal blocks after liver transplantation using bupivacaine in three patients [4] . This study used smaller total doses of 50-100 mg, making comparison of data difficult, but Cmax occurred at times similar to our data at 5 min, the first sampling time. Increased plasma concentrations of local anaesthetic may be a problem with intercostal blocks [5, 6] because of the large total volumes of drug solution required for multiple injections in a normally vascular area. In patients with advanced liver disease, the chest wall may have unusually large venous vessels because of porto-systemic anastomoses. These collateral vessels may alter the rate of drug absorption after intercostal injection.
The mean concentrations of bupivacaine were within ranges similar to those reported in other series [5] [6] [7] . There was no statistical difference between Cmax for the two groups with and without adrenaline. In group 1, the observation that Cmax occurred at 5 min in two patients not given adrenaline suggests that Cmax may have occurred earlier in some of these patients. In group II an additional sample was collected at 2.5 min, following reports of Cmax occurring early [7] . No Cmax values were seen at 2.5 min in group 2. Tmax was variable between patients in both groups, but these cannot be compared reliably because of the spacing of sampling times and the relatively small numbers of patients studied. The addition of adrenaline to the bupivacaine solution did not consistently increase the time taken to reach Cmax and this is in disagreement with other studies measuring arterial concentrations of bupivacaine after intercostal injection [7] . The abnormal vessels of patients with liver disease may not vasoconstrict normally in the presence of injected adrenaline. In addition, the size of the collateral vessels may not be important. Studies in children with extensive collateral vessel formation secondary to coarctation of the aorta have demonstrated that absorption of bupivacaine is the same as that of children with other forms of congenital heart disease without collateral vessel formation [6] .
No adverse reactions were seen in these patients, despite plasma concentrations of bupi-vacaine within the putative toxic range in six patients (two in group 1, four in group 2 following both sets of injections). This may reflect an inaccuracy of the reported toxic threshold of 2-4 ug ml" 1 [8, 9] for bupivacaine. The reported toxic values have been derived from studies using short i.v. infusions of bupivacaine to obtain steady state concentrations. However, differences in the analytical method, sampling sites and infusion regimen used in these studies make interpretation difficult [10] . Alternatively, the lack of adverse side effects may be a reflection of residual benzodiazepine sedation, which had been administered before tracheal extubation [11] . All patients in the study were reusable but had residual sedation and analgesia, making neurological assessment difficult. In addition, the total bupivacaine concentrations measured in our study may not reflect the free, non-protein-bound concentration of the drug which is thought to cause CNS side effects [12] .
Bupivacaine is bound extensively to AGP [13] , an acute phase reactant with concentrations that were increased in these and other patients following liver transplantation, because of acute surgical stress and liver disease [Shelly, Walker, Burns and Park, unpublished observation]. In the presence of increased concentrations of AGP, increased total concentrations of bupivacaine would be measured, but toxicity might not occur, as the free concentration would be less. The concentrations of AGP were greater than the reference range (0.5-1.0 g litre" 1 ) in seven of the patients in this study, but did not correspond to those with increased total bupivacaine concentrations. Unfortunately, it was not possible to measure free bupivacaine concentrations or the differing subtypes of AGP [14, 15] and their differing effects (if any) on drug binding. The relatively normal albumin and total protein concentrations reflect aggressive treatment of hypoalbuminaemia by infusion of albumin-containing solutions in the perioperative period.
Other factors also may have contributed to the increased plasma concentrations of bupivacaine. Uptake of bupivacaine by the lungs is significant [16] and may be inhibited competitively by drugs such as propranolol [17] . Three patients had been receiving propranolol for control of portal hypertension before liver transplant. However, these three patients did not develop consistently greater bupivacaine concentrations than the other patients studied. The presence of functional intrapulmonary shunting in patients with liver disease [18] may also increase the availability of the drug to the systemic circulation. This has been shown experimentally in animals, using lignocaine [19] .
Bupivacaine is metabolized by the liver, with a lesser hepatic extraction ratio than lignocaine [10, 20] . Little is known of drug metabolism shortly after liver transplantation, but studies to date have shown both normal and abnormal pharmacokinetics for several drugs. The transplanted liver is subject to insults during two operations (removal from the donor and insertion into the recipient), with a varying ischaemic time between. Clinical studies have shown that clearance of lignocaine may be impaired in patients with cirrhosis [21] , after hepatectomy [22] , and during viral hepatitis [23] . No data exist for bupivacaine.
Extrapolation of these results to other patients with liver disease requires caution, as differences in the mechanisms of liver injury may alter its capacity to eliminate bupivacaine. However, the results suggest that caution may be necessary in this group of patients when intercostal blocks are performed. Some patients may achieve potentially toxic plasma concentrations of bupivacaine at a variable time after performing the intercostal nerve blocks. The use of adrenaline-containing solutions did not consistently reduce the speed of absorption or the maximum concentration of bupivacaine. Furthermore, bupivacaine cumulation after repeated intercostal nerve blocks within 6-8 h may occur in some patients following liver transplantation, and possibly others with hepatic dysfunction.
